Exploring 3 Promising Undervalued Small Caps With Insider Action Across Regions

The United States market has experienced a 13% drop over the past week, despite having risen by the same percentage over the last year, with earnings projected to grow annually by 17%. In such a fluctuating environment, identifying promising small-cap stocks with insider activity can be an effective strategy for uncovering potential opportunities.

Top 10 Undervalued Small Caps With Insider Buying In The United States

Name	PE	PS	Discount to Fair Value	Value Rating
Regional Management	6.5x	0.5x	35.38%	★★★★★★
Enovis	NA	0.5x	45.43%	★★★★★☆
Bank of Marin Bancorp	NA	7.3x	29.54%	★★★★☆☆
Bank of the James Financial Group	11.0x	2.5x	25.56%	★★★★☆☆
Union Bankshares	9.8x	2.1x	45.04%	★★★★☆☆
Shore Bancshares	11.8x	3.4x	35.79%	★★★★☆☆
Five Star Bancorp	15.8x	6.8x	42.61%	★★★☆☆☆
German American Bancorp	13.1x	4.9x	26.13%	★★★☆☆☆
Peoples Financial	30.3x	4.1x	30.04%	★★★☆☆☆
Orion Group Holdings	101.8x	0.4x	45.73%	★★★☆☆☆

Click here to see the full list of 54 stocks from our Undervalued US Small Caps With Insider Buying screener.

We're going to check out a few of the best picks from our screener tool.

Parke Bancorp (PKBK)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Parke Bancorp operates as a community bank providing financial services, with a focus on traditional banking products and services, and has a market capitalization of approximately $0.22 billion.

Operations: Parke Bancorp's revenue is primarily derived from community banking, with a recent figure of $88.83 million. The company operates with a gross profit margin consistently at 100%. Operating expenses have been increasing, reaching $26.88 million recently, contributing to fluctuations in net income margins which were last recorded at 51.53%.

PE: 8.9x

Parke Bancorp, a smaller player in the U.S. financial sector, has shown significant insider confidence with recent share purchases. Despite earnings declining by 3% annually over the past five years, the company reported strong second-quarter results for 2026. Net interest income rose to US$23.01 million from US$17.87 million year-over-year, while net income increased to US$12.24 million from US$8.28 million last year, reflecting potential value amidst its challenges and opportunities in banking services expansion.

• Get an in-depth perspective on Parke Bancorp's performance by reading our valuation report here.

• Learn about Parke Bancorp's historical performance.

Anika Therapeutics (ANIK)

Simply Wall St Value Rating: ★★★★★☆

Overview: Anika Therapeutics is a company specializing in the development and commercialization of therapeutic products for tissue protection, healing, and repair, with a market cap of approximately $0.51 billion.

Operations: The company generates revenue primarily from its Medical Products segment, with a recent quarterly revenue of $120.65 million. The cost of goods sold for this period was $45.65 million, resulting in a gross profit margin of 62.16%. Operating expenses were reported at $77.60 million, which includes research and development costs amounting to $27.45 million and general and administrative expenses totaling $50.15 million, contributing to the net income loss observed during this period.

PE: -90.0x

Anika Therapeutics, a small-cap company, has shown signs of being undervalued with recent insider confidence reflected in share repurchases. From April to June 2026, they bought back 56,761 shares for US$0.85 million. Despite relying on higher-risk external funding sources and being dropped from some indexes in June 2026, Anika raised its earnings guidance for fiscal year 2026 and reported improved Q2 results with sales reaching US$32.61 million compared to last year's US$28.22 million.

• Click to explore a detailed breakdown of our findings in Anika Therapeutics' valuation report.

• Assess Anika Therapeutics' past performance with our detailed historical performance reports.

Huntsman (HUN)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Huntsman is a global manufacturer and marketer of differentiated and specialty chemicals, with a market capitalization of approximately $4.90 billion, operating primarily in the polyurethanes, advanced materials, and performance products segments.

Operations: Huntsman's revenue is primarily derived from Polyurethanes, Advanced Materials, and Performance Products segments. The company has experienced fluctuations in its net income margin, with a notable decline to -5.67% by March 2026. Its cost of goods sold (COGS) consistently represents a significant portion of revenue, impacting gross profit margins which have seen a downward trend reaching 12.88% in March 2026. Operating expenses also play a crucial role in affecting profitability levels over the periods analyzed.

PE: -9.9x

Huntsman, a smaller player in the U.S. market, has recently attracted attention due to insider confidence. Chairman Peter Huntsman purchased 100,000 shares for US$981,000 between April and June 2026. This move suggests belief in the company's potential amid its merger with Olin Corporation, valued at approximately US$1.7 billion. Despite challenges like external borrowing risks and recent net losses of US$59 million over six months ending June 2026, earnings are forecasted to grow significantly by 113% annually.

• Navigate through the intricacies of Huntsman with our comprehensive valuation report here.

• Gain insights into Huntsman's historical performance by reviewing our past performance report.

Next Steps

• Dive into all 54 of the Undervalued US Small Caps With Insider Buying we have identified here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com